WPRIM Management System> DCMS> Asian Journal of Andrology> 2018> 20> 2

Volume: 20 Issue: 2

1. Testosterone and its metabolites: Differential associations with cardiovascular and cerebrovascular events in men Page:109—114
2. Endogenous testosterone and mortality risk Page:115—119
3. Randomized controlled trials-mechanistic studies of testosterone and the cardiovascular system Page:120—130
4. Trials of testosterone replacement reporting cardiovascular adverse events Page:131—137
5. Testosterone treatment and cardiovascular events in prescription database studies Page:138—144
6. Would male hormonal contraceptives affect cardiovascular risk? Page:145—148
7. The expression of the new epididymal luminal protein of PDZ domain containing 1 is decreased in asthenozoospermia Page:154—159
8. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Evidence from patients in Northwestern China Page:173—177
9. Phosphoglycerate mutase 1 knockdown inhibits prostate cancer cell growth, migration, and invasion Page:178—183
10. External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer Page:184—188
11. A retrospective review of single-institution outcomes with robotic-assisted microsurgical varicocelectomy Page:189—194
12. Association of subcutaneous testosterone pellet therapy with developing secondary polycythemia Page:195—199
13. Andrographolide sensitizes prostate cancer cells to TRAIL-induced apoptosis Page:200—204
14. Lipoxin A4 improves erectile dysfunction in rats with type i diabetes by inhibiting oxidative stress and corporal fibrosis Page:166—172
15. An in vitro prototype of a porcine biomimetic testis-like cell culture system: A novel tool for the study of reassembled Sertoli and Leydig cells Page:160—165
16. Diagnosis of a Chinese man with 45,X/46,X,i(Y)(q10)/47,X,i(Y) (q10) ×2 mosaic Turner syndrome. Page:205—207
17. Globozoospermic infertility associated with balanced DPY19L2 translocation/gene deletion at the chromosomal breakpoint. Page:210—211
18. Trials of testosterone replacement reporting cardiovascular adverse events. Page:131—137
19. Testosterone treatment and cardiovascular events in prescription database studies. Page:138—144
20. Andrographolide sensitizes prostate cancer cells to TRAIL-induced apoptosis. Page:200—204
21. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. Page:173—177
22. Fertility achieved through in vitro fertilization in a male patient with 48,XXYY syndrome. Page:208—209
23. A retrospective review of single-institution outcomes with robotic-assisted microsurgical varicocelectomy. Page:189—194
24. External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer. Page:184—188
25. Lipoxin A4 improves erectile dysfunction in rats with type I diabetes by inhibiting oxidative stress and corporal fibrosis. Page:166—172
26. An in vitro prototype of a porcine biomimetic testis-like cell culture system: a novel tool for the study of reassembled Sertoli and Leydig cells. Page:160—165
27. Testosterone and its metabolites: differential associations with cardiovascular and cerebrovascular events in men. Page:109—114
28. Association of subcutaneous testosterone pellet therapy with developing secondary polycythemia. Page:195—199
29. Commentary on "Nondegloving technique for Peyronie's disease with penile prosthesis implantation and double dorsal-ventral patch graft". Page:212—212
30. Phosphoglycerate mutase 1 knockdown inhibits prostate cancer cell growth, migration, and invasion. Page:178—183
31. Would male hormonal contraceptives affect cardiovascular risk? Page:145—148
32. Endogenous testosterone and mortality risk. Page:115—119
33. The expression of the new epididymal luminal protein of PDZ domain containing 1 is decreased in asthenozoospermia. Page:154—159
34. Testosterone replacement therapy: Dilemmas and challenges in China and Asia. Page:149—151
35. Why is understanding the relationship of testosterone to cardiovascular risk so important? Page:107—108
36. Randomized controlled trials - mechanistic studies of testosterone and the cardiovascular system. Page:120—130
37. Conclusions about testosterone therapy and cardiovascular risk. Page:152—153